1. Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging
- Author
-
Fundación BBVA, Mulero, Francisca [0000-0001-9584-4211], Oteo, Marta [0000-0002-2855-3403], Garaulet, Guillermo [0000-0002-8555-5173], Magro, Natalia [0000-0002-6212-1401], Santiveri, Clara M. [0000-0001-6095-7224], Romero, Eduardo [0000-0003-1347-1947], Sellek, Ricela E. [0000-0001-9249-7453], Margolles, Yago [0000-0003-1413-060X], Campos-Olivas, Ramón [0000-0002-5743-2221], Arroyo, Alicia G. [0000-0002-1536-3846], Fernández, Luis Ángel [0000-0001-5920-0638], Morcillo, Miguel Ángel [0000-0002-1984-5834], Martínez-Torrecuadrada, Jorge Luis [0000-0002-8240-6623], Mulero, Francisca, Oteo, Marta, Garaulet, Guillermo, Magro, Natalia, Rebollo, Lluvia, Medrano, Guillermo, Santiveri, Clara M., Romero, Eduardo, Sellek, Ricela E., Margolles, Yago, Campos-Olivas, Ramón, Arroyo, Alicia G., Fernández, Luis Ángel, Morcillo, Miguel Ángel, Martínez-Torrecuadrada, Jorge Luis, Fundación BBVA, Mulero, Francisca [0000-0001-9584-4211], Oteo, Marta [0000-0002-2855-3403], Garaulet, Guillermo [0000-0002-8555-5173], Magro, Natalia [0000-0002-6212-1401], Santiveri, Clara M. [0000-0001-6095-7224], Romero, Eduardo [0000-0003-1347-1947], Sellek, Ricela E. [0000-0001-9249-7453], Margolles, Yago [0000-0003-1413-060X], Campos-Olivas, Ramón [0000-0002-5743-2221], Arroyo, Alicia G. [0000-0002-1536-3846], Fernández, Luis Ángel [0000-0001-5920-0638], Morcillo, Miguel Ángel [0000-0002-1984-5834], Martínez-Torrecuadrada, Jorge Luis [0000-0002-8240-6623], Mulero, Francisca, Oteo, Marta, Garaulet, Guillermo, Magro, Natalia, Rebollo, Lluvia, Medrano, Guillermo, Santiveri, Clara M., Romero, Eduardo, Sellek, Ricela E., Margolles, Yago, Campos-Olivas, Ramón, Arroyo, Alicia G., Fernández, Luis Ángel, Morcillo, Miguel Ángel, and Martínez-Torrecuadrada, Jorge Luis
- Abstract
Triple-negative breast cancer (TNBC) is characterized by aggressiveness and high rates of metastasis. The identification of relevant biomarkers is crucial to improve outcomes for TNBC patients. Membrane type 1-matrix metalloproteinase (MT1-MMP) could be a good candidate because its expression has been reported to correlate with tumor malignancy, progression and metastasis. Moreover, single-domain variable regions (VHHs or Nanobodies) derived from camelid heavy-chain-only antibodies have demonstrated improvements in tissue penetration and blood clearance, important characteristics for cancer imaging. Here, we have developed a nanobody-based PET imaging strategy for TNBC detection that targets MT1-MMP. A llama-derived library was screened against the catalytic domain of MT1-MMP and a panel of specific nanobodies were identified. After a deep characterization, two nanobodies were selected to be labeled with gallium-68 (68Ga). ImmunoPET imaging with both ([68Ga]Ga-NOTA-3TPA14 and [68Ga]Ga-NOTA-3CMP75) in a TNBC mouse model showed precise tumor-targeting capacity in vivo with high signal-to-background ratios. (68Ga)Ga-NOTA-3CMP75 exhibited higher tumor uptake compared to (68Ga)Ga-NOTA-3TPA14. Furthermore, imaging data correlated perfectly with the immunohistochemistry staining results. In conclusion, we found a promising candidate for nanobody-based PET imaging to be further investigated as a diagnostic tool in TNBC.
- Published
- 2022